Anika Therapeutics reported $14.89M in Cost of Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Abbott ABT:US $ 4987M 267M
Acorda Therapeutics ACOR:US $ 5.97M 1.77M
Agenus AGEN:US $ 543K 338K
Anika Therapeutics ANIK:US $ 14.89M 2.8M
ChemoCentryx CCXI:US 205K 97K
Clovis Oncology CLVS:US $ 9.41M 0.32M
Halozyme Therapeutics HALO:US $ 15.92M 5.66M
Heron Therapeutics HRTX:US $ 11.36M 0.41M
Insmed INSM:US $ 12.19M 1.1M
Integra Lifesciences IART:US $ 138.04M 12.63M
Intrexon XON:US $ 17.1M 2.17M
Johnson & Johnson JNJ:US $ 7598M 357M
Karyopharm Therapeutics KPTI:US $ 1.43M 684K
Ligand Pharmaceuticals LGND:US $ 4.7M 7.28M
MacroGenics MGNX:US 48K 899K
Merit Medical Systems MMSI:US $ 154.51M 4.82M
Peregrine Pharmaceuticals PPHM:US $ 22.42M 5.5M
Rigel Pharmaceuticals RIGL:US $ 0.12M 0.37M
Stryker SYK:US $ 1548M 154M
Surmodics SRDX:US $ 5.11M 0.61M
Veracyte VCYT:US $ 23.71M 0.83M
Zimmer Biomet Holdings Inc ZBH:US $ 500M 161.5M